{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:46:32Z","timestamp":1792547192333,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Primary axillary hyperhidrosis (PAHH) strongly affects the patient's quality of life. To date, topical treatment options are limited. One percent glycopyrronium bromide (GPB) showed promising efficacy and safety in a pivotal 4\u2010week Phase 3a study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess efficacy and safety of topical 1% GPB cream in patients with severe PAHH in a long\u2010term study of 72\u2009weeks versus baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a long\u2010term, open\u2010label, Phase 3b trial for 72\u2009weeks including 518 patients with severe PAHH. Patients were treated with 1% GPB cream once daily for 4\u2009weeks, followed by a flexible dosing scheme (min. twice per week, max. once daily). Primary endpoint was the absolute change in sweat production from baseline to week 12. Further study endpoints included assessment of the severity of PAHH and the impact on quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Total median sweat production decreased by 119.30\u2009mg (\u221265.6%, both median) until week 12. Absolute change in sweat production from baseline to week 12 in logarithmic values was statistically significant (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Patients' quality of life was improved at all study time points compared to baseline, as assessed by Hyperhidrosis Quality of Life Index and Dermatology Life Quality Index (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Treatment was safe and locally well\u2010tolerated with only few mild to moderate adverse drug reactions (ADRs). Dry mouth and application site erythema were the most common reported ADRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with 1% GPB cream over 72\u2009weeks significantly reduces sweat production and improves quality of life in patients with severe PAHH. One percent GPB cream is well\u2010tolerated and provides an effective treatment option for long\u2010term use in patients with severe PAHH.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18843","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T10:30:25Z","timestamp":1673001025000},"page":"823-830","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long\u2010term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial"],"prefix":"10.1111","volume":"37","author":[{"given":"Rolf\u2010Markus","family":"Szeimies","sequence":"first","affiliation":[{"name":"Klinikum Vest GmbH  Recklinghausen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-7740","authenticated-orcid":false,"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"},{"name":"Bionorica SE  Neumarkt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kilic","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Reich","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Berger","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Schulze\u00a0zur\u00a0Wiesche","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schramm","sequence":"additional","affiliation":[{"name":"FGK Clinical Research GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Litzka","sequence":"additional","affiliation":[{"name":"FGK Clinical Research GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Heimstaedt\u2010Muskett","sequence":"additional","affiliation":[{"name":"FGK Clinical Research GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-727X","authenticated-orcid":false,"given":"Clarissa","family":"Masur","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH &amp; Co. KG Arzneimittel  Bielefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2016.06.002"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-018-4265-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14378"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351292"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040708"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.001"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2020.1857149"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587870-000000000-00000"},{"issue":"5","key":"e_1_2_9_11_1","first-page":"477","article-title":"An open\u2010label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate\u2010to\u2010severe primary axillary hyperhidrosis","volume":"8","author":"Flanagan KH","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14354"},{"key":"e_1_2_9_13_1","unstructured":"Drug approval package: Qbrexza (glycopyrronium). 2018 [cited 2022 Jun 7]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210361Orig1s000TOC.cfm"},{"key":"e_1_2_9_14_1","unstructured":"Maruho receives manufacturing and marketing approval for primary axillary hyperhidrosis treatment \u201cRapifort\u00ae Wipes 2.5%\u201d in Japan. 2022 [cited 2022 Jun 7]. Available from:https:\/\/www.maruho.co.jp\/english\/information\/2022\/01\/20220120_pr_eng.pdf"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01438-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.03.016"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18234"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19810"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.10.202"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0825-2"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19300"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00446-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15927"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15164"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)63957-5"},{"issue":"8","key":"e_1_2_9_27_1","first-page":"908","article-title":"A comprehensive approach to the recognition, diagnosis, and severity\u2010based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee","volume":"33","author":"Solish N","year":"2007","journal-title":"Dermatol Surg"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1506080"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18843","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:10:17Z","timestamp":1695211817000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/jdv.18843"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18843","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"assertion":[{"value":"2022-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}